Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026)
Kamada's (KMDA) quarterly Total Non-Current Liabilities came in at $63.9 million in Q1 2026, down 3.39% YoY from $66.1 million in Q1 2025, and up 2.59% on a QoQ basis from $62.2 million in Q4 2025.
Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Kamada (KMDA) has 13 years of Total Non-Current Liabilities data on file, last reported at $63.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 3.39% year-over-year to $63.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.9 million (down 3.39% YoY) and the FY2025 annual result came in at $62.2 million, down 1.82% from the prior year.
- Total Non-Current Liabilities grew to $63.9 million in Q1 2026, from $62.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $85.7 million in Q1 2022 to a low of -$8.1 million in Q4 2024.
- A 5-year average of $50.8 million and a median of $62.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 78674.89% — and 2024, when it plunged 439.82%.
- Tracing KMDA's Total Non-Current Liabilities over 5 years: stood at $70.7 million in 2022, then sank by 96.63% to $2.4 million in 2023, then sank by 439.82% to -$8.1 million in 2024, then surged by 870.28% to $62.2 million in 2025, then gained by 2.59% to $63.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $63.9 million (Q1 2026), $62.2 million (Q4 2025), and $64.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Kamada | 463.48 Mn | 434.00 Mn | 22.47 Mn | 64.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.45 Mn |
| Mar 31, 2026 | 63.86 Mn |
| Dec 31, 2025 | 62.25 Mn |
| Sep 30, 2025 | 64.14 Mn |
| Jun 30, 2025 | 62.45 Mn |
| Mar 31, 2025 | 66.10 Mn |
| Dec 31, 2024 | -8.08 Mn |
| Sep 30, 2024 | 61.94 Mn |
| Jun 30, 2024 | 58.99 Mn |
| Mar 31, 2024 | 59.49 Mn |
| Dec 31, 2023 | 2.38 Mn |
| Sep 30, 2023 | 61.39 Mn |
| Jun 30, 2023 | 71.81 Mn |
| Mar 31, 2023 | -1.76 Mn |
| Dec 31, 2022 | 70.65 Mn |
| Sep 30, 2022 | 77,936.00 |
| Jun 30, 2022 | 82.88 Mn |
| Mar 31, 2022 | 85.72 Mn |
| Dec 31, 2021 | 87.79 Mn |
| Sep 30, 2021 | 8.33 Mn |